ANI Score Is Not Validated for Decompensated Cirrhosis
The Alcoholic/Non-Alcoholic Fatty Liver Disease Index (ANI) was developed and validated exclusively in patients with steatohepatitis, not decompensated cirrhosis, and should not be used in this population.
Evidence Base and Limitations
The ANI score was originally derived to distinguish alcoholic liver disease (ALD) from non-alcoholic fatty liver disease (NAFLD) in patients with steatohepatitis 1. The model uses four variables: mean corpuscular volume, AST/ALT ratio, body mass index, and gender. While it demonstrated excellent discrimination in the original validation cohorts (c-statistic 0.767-0.989), these populations consisted of hospitalized, ambulatory, and pre-transplantation patients with steatohepatitis—not specifically patients with decompensated cirrhosis 1.
Why This Matters in Decompensated Cirrhosis
Decompensated cirrhosis represents a fundamentally different clinical entity from the steatohepatitis populations where ANI was validated. Key considerations include:
Altered laboratory parameters: Patients with decompensated cirrhosis present with jaundice, ascites, variceal bleeding, hepatorenal syndrome, and hepatic encephalopathy 2. These complications profoundly alter the biochemical markers that ANI relies upon, independent of alcohol etiology.
Multi-organ dysfunction: Decompensation involves systemic inflammation, circulatory dysfunction, and organ failures that confound the simple laboratory ratios used in ANI 3.
Different prognostic priorities: In decompensated cirrhosis, established scores like MELD, Child-Pugh, and CLIF-C AD are validated for mortality prediction 3, 2. The clinical question shifts from etiology determination to risk stratification and transplant candidacy.
Recent Attempts at Application
A 2026 pilot study attempted to use ANI in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) to identify unrecognized alcohol consumption 4. Critically, the authors themselves acknowledge that "the ANI score is not validated to distinguish MetALD from MASLD" and their findings were in patients without decompensation 4. This underscores that even in compensated disease with different etiologies, ANI's utility remains uncertain.
What to Use Instead
For patients with decompensated cirrhosis:
- Prognostic assessment: Use MELD score, Child-Pugh score, or CLIF-C AD score for mortality prediction 3, 2
- Etiology determination: Rely on comprehensive clinical history (including collateral informants for alcohol use), pattern of decompensation (ascites predominates in alcoholic cirrhosis), and histopathology when available 2
- Biomarkers for prognosis: In decompensated cirrhosis, albumin, INR, bilirubin, and platelet count are validated prognostic markers 5, 6
Clinical Pitfall
Do not apply ANI in decompensated cirrhosis assuming it retains diagnostic accuracy. The score's components (MCV, AST/ALT ratio, BMI) are all significantly altered by the metabolic derangements, nutritional deficiencies, and systemic complications inherent to decompensation, regardless of whether alcohol was the original trigger.